<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35130111</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1555-8576</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer biology &amp; therapy</Title>
          <ISOAbbreviation>Cancer Biol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β.</ArticleTitle>
        <Pagination>
          <StartPage>150</StartPage>
          <EndPage>162</EndPage>
          <MedlinePgn>150-162</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384047.2022.2035629</ELocationID>
        <Abstract>
          <AbstractText>Transforming growth factor-β (TGF-β) plays a critical role in regulating cell growth and differentiation. Epithelial to mesenchymal transition (EMT) induced by TGF-β promotes cancer cell migration, invasion, and proliferation. Pirfenidone (5-methyl-1-phenyl-2(1 H)-pyridone, PFD), an approved drug for treating pulmonary and renal fibrosis, is a potent TGF-β inhibitor and found reduced incidence of lung cancer and alleviated renal function decline. However, whether PFD plays a role in controlling renal cancer progression is largely unknown. In the present study, we demonstrated that high TGF-β1 expression was negatively associated with ten-year overall survival of patients with renal cancer. Functionally, blockade of TGF-β signaling with PFD significantly suppressed the progression of renal cancer in a murine model. Mechanistically, we revealed that PFD significantly decreased the expression and secretion of TGF-β both in vitro and in vivo tumor mouse model, which further prevented TGF-β-induced EMT and thus cell proliferation, migration, and invasion. Importantly, the downregulation of TGF-β upon PFD treatment shaped the immunosuppressive tumor microenvironment by limiting the recruitment of tumor-infiltrating MDSCs. Therefore, our study demonstrated that PFD prevents renal cancer progression by inhibiting TGF-β production of cancer cells and downstream signaling pathway, which might be presented as a therapeutic adjuvant for renal cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-6020-7263</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xiaowan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Zengli</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Nan</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Juan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Yanfang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Lulu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Dandan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chai</LastName>
            <ForeName>Dafei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Huizhong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Liantao</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Junnian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Biol Ther</MedlineTA>
        <NlmUniqueID>101137842</NlmUniqueID>
        <ISSNLinking>1538-4047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011728">Pyridones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>D7NLD2JX7U</RegistryNumber>
          <NameOfSubstance UI="C093844">pirfenidone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002292" MajorTopicYN="Y">Carcinoma, Renal Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007680" MajorTopicYN="Y">Kidney Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Pirfenidone</Keyword>
        <Keyword MajorTopicYN="Y">TGF-β</Keyword>
        <Keyword MajorTopicYN="Y">epithelial-to-mesenchymal transition</Keyword>
        <Keyword MajorTopicYN="Y">myeloid-derived suppressor cells (MDSC)</Keyword>
        <Keyword MajorTopicYN="Y">renal cell carcinoma</Keyword>
        <Keyword MajorTopicYN="Y">tumor microenvironment (TME)</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>17</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35130111</ArticleId>
        <ArticleId IdType="pmc">PMC8824226</ArticleId>
        <ArticleId IdType="doi">10.1080/15384047.2022.2035629</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.. 
2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249. 10.3322/caac.21660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21660</ArticleId>
            <ArticleId IdType="pubmed">33538338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen F, Liu X, Cheng Q, Zhu S, Bai J, Zheng J. 2017. RUNX3 regulates renal cell carcinoma metastasis via targeting miR-6780a-5p/E-cadherin/EMT signaling axis. Oncotarget. 8(60):101042–101056. 10.18632/oncotarget.13205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.13205</ArticleId>
            <ArticleId IdType="pmc">PMC5731854</ArticleId>
            <ArticleId IdType="pubmed">29254144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ouzaid I, Capitanio U, Staehler M, Wood CG, Leibovich BC, Ljungberg B, Van Poppel H, Bensalah K. 2019. Surgical Metastasectomy in Renal Cell Carcinoma: a Systematic Review. Eur Urol Oncol. 2(2):141–149. 10.1016/j.euo.2018.08.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.euo.2018.08.028</ArticleId>
            <ArticleId IdType="pubmed">31017089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Speed JM, Trinh QD, Choueiri TK, Sun M. 2017. Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. Curr Urol Rep. 18(2):15. 10.1007/s11934-017-0661-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11934-017-0661-3</ArticleId>
            <ArticleId IdType="pubmed">28213859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. 2016. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: renal, Penile, and Testicular Tumours. Eur Urol. 70(1):93–105. 10.1016/j.eururo.2016.02.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2016.02.029</ArticleId>
            <ArticleId IdType="pubmed">26935559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coppin C. 2008. Sunitinib for advanced renal cell cancer. Biologics. 2(1):97–105. 10.2147/btt.s1834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/btt.s1834</ArticleId>
            <ArticleId IdType="pmc">PMC2727778</ArticleId>
            <ArticleId IdType="pubmed">19707433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis FM, Stewart TA, Thompson EW, Monteith GR. 2014. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci. 35(9):479–488. 10.1016/j.tips.2014.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2014.06.006</ArticleId>
            <ArticleId IdType="pubmed">25042456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao LJ, Yang CH, Fan L, Gao P, Yang DR, Xue BX, Zheng J-N, Shan Y-X. 2016. SATB1 promotes prostate cancer metastasis by the regulation of epithelial-mesenchymal transition. Biomed Pharmacother. 79:1–8. 10.1016/j.biopha.2016.01.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2016.01.038</ArticleId>
            <ArticleId IdType="pubmed">27044805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. 2017. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol. 11(7):805–823. 10.1002/1878-0261.12095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12095</ArticleId>
            <ArticleId IdType="pmc">PMC5496491</ArticleId>
            <ArticleId IdType="pubmed">28599100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Kim TY, Lee MS, Mun JY, Ihm C, Kim SA. 2016. Exosome cargo reflects TGF-beta1-mediated epithelial-to-mesenchymal transition (EMT) status in A549 human lung adenocarcinoma cells. Biochem Biophys Res Commun. 478(2):643–648. 10.1016/j.bbrc.2016.07.124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.07.124</ArticleId>
            <ArticleId IdType="pubmed">27492069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahman MA, Barger JF, Lovat F, Gao M, Otterson GA, Nana-Sinkam P. 2016. Lung cancer exosomes as drivers of epithelial mesenchymal transition. Oncotarget. 7(34):54852–54866. 10.18632/oncotarget.10243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.10243</ArticleId>
            <ArticleId IdType="pmc">PMC5342386</ArticleId>
            <ArticleId IdType="pubmed">27363026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Li T, Yan F, Cai WY, Zheng JW, Jiang XY, Sun J. 2018. Effect of simvastatin and microRNA-21 inhibitor on metastasis and progression of human salivary adenoid cystic carcinoma. Biomedicine &amp; Pharmacotherapy. 105:1054–1061. 10.1016/j.biopha.2018.05.157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.05.157</ArticleId>
            <ArticleId IdType="pubmed">30021341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wunderlich H, Steiner T, Kosmehl H, Junker U, Reinhold D, Reichelt O, Zermann DH, Schubert J. 1998. Increased transforming growth factor beta1 plasma level in patients with renal cell carcinoma: a tumor-specific marker?
Urol Int. 60(4):205–207. 10.1159/000030255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000030255</ArticleId>
            <ArticleId IdType="pubmed">9701731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kou B, Liu W, Tang X, Kou Q. 2018. HMGA2 facilitates epithelial-mesenchymal transition in renal cell carcinoma by regulating the TGF-beta/Smad2 signaling pathway. Oncol Rep. 39(1):101–108. 10.3892/or.2017.6091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2017.6091</ArticleId>
            <ArticleId IdType="pmc">PMC5783590</ArticleId>
            <ArticleId IdType="pubmed">29138866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amerizadeh F, Bahrami A, Khazaei M, Hesari A, Rezayi M, Talebian S, Maftouh M, Moetamani‐Ahmadi M, Seifi S, Shahidsales S, et al. 2019. Current status and future prospects of transforming growth factor-beta as a potential prognostic and therapeutic target in the treatment of breast cancer. J Cell Biochem. 120(5):6962–6971. DOI:10.1002/jcb.27831</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.27831</ArticleId>
            <ArticleId IdType="pubmed">30672016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikushima H, Miyazono K. 2010. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 10(6):415–424. 10.1038/nrc2853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2853</ArticleId>
            <ArticleId IdType="pubmed">20495575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. 2004. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 23(5):1155–1165. 10.1038/sj.emboj.7600069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.emboj.7600069</ArticleId>
            <ArticleId IdType="pmc">PMC380966</ArticleId>
            <ArticleId IdType="pubmed">14976548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. 2014. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 58:13–19. 10.1016/j.ejps.2014.02.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejps.2014.02.014</ArticleId>
            <ArticleId IdType="pubmed">24613900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu B, Rong Y, Sun D, Li W, Chen H, Cao B, Wang T. 2019. Costunolide inhibits pulmonary fibrosis via regulating NF-kB and TGF-beta1/Smad2/Nrf2-NOX4 signaling pathways. Biochem Biophys Res Commun. 510(2):329–333. 10.1016/j.bbrc.2019.01.104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.01.104</ArticleId>
            <ArticleId IdType="pubmed">30709583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cottin V. 2013. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res. 14 Suppl 1(S1):S5. 10.1186/1465-9921-14-S1-S5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1465-9921-14-S1-S5</ArticleId>
            <ArticleId IdType="pmc">PMC3643400</ArticleId>
            <ArticleId IdType="pubmed">23734908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruwanpura SM, Thomas BJ, Bardin PG. 2020. Pirfenidone: molecular Mechanisms and Potential Clinical Applications in Lung Disease. Am J Respir Cell Mol Biol. 62(4):413–422. 10.1165/rcmb.2019-0328TR.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2019-0328TR</ArticleId>
            <ArticleId IdType="pubmed">31967851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burghardt I, Tritschler F, Opitz CA, Frank B, Weller M, Wick W. 2007. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 354(2):542–547. 10.1016/j.bbrc.2007.01.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2007.01.012</ArticleId>
            <ArticleId IdType="pubmed">17234158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi SH, Nam JK, Jang J, Lee HJ, Lee YJ. 2015. Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy. Biochem Biophys Res Commun. 462(2):138–143. 10.1016/j.bbrc.2015.04.107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2015.04.107</ArticleId>
            <ArticleId IdType="pubmed">25935484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozono S, Ohuchida K, Eguchi D, Ikenaga N, Fujiwara K, Cui L, Mizumoto, K, Tanaka, M.. 
2013. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res. 73(7):2345–2356. DOI:10.1158/0008-5472.CAN-12-3180</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-3180</ArticleId>
            <ArticleId IdType="pubmed">23348422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee BS, Margolin SB, Nowak RA. 1998. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab. 83(1):219–223. 10.1210/jcem.83.1.4503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.83.1.4503</ArticleId>
            <ArticleId IdType="pubmed">9435445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mediavilla-Varela M, Boateng K, Noyes D, Antonia SJ. 2016. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer. 16(1):176. 10.1186/s12885-016-2162-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-016-2162-z</ArticleId>
            <ArticleId IdType="pmc">PMC4776434</ArticleId>
            <ArticleId IdType="pubmed">26935219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suklabaidya S, Das B, Ali SA, Jain S, Swaminathan S, Mohanty AK, Panda SK, Dash P, Chakraborty S, Batra SK, et al. 2016. Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia. Oncotarget. 7(27):41825–41842. DOI:10.18632/oncotarget.9729</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.9729</ArticleId>
            <ArticleId IdType="pmc">PMC5173099</ArticleId>
            <ArticleId IdType="pubmed">27259232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takai K, Le A, Weaver VM, Werb Z. 2016. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget. 7(50):82889–82901. 10.18632/oncotarget.12658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.12658</ArticleId>
            <ArticleId IdType="pmc">PMC5341254</ArticleId>
            <ArticleId IdType="pubmed">27756881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marwitz S, Turkowski K, Nitschkowski D, Weigert A, Brandenburg J, Reiling N, Thomas M, Reck M, Dromann D, Seeger W, et al. 2019. The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC. Front Oncol. 9:1550. 10.3389/fonc.2019.01550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.01550</ArticleId>
            <ArticleId IdType="pmc">PMC6985561</ArticleId>
            <ArticleId IdType="pubmed">32039023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin W, Zou J, Huang YB, Liu CF, Kang YL, Han H, Tang Y, Li L, Liu B, Zhao WH, et al. 2020. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. Oncoimmunology. 9(1):1824631. 10.1080/2162402X.2020.1824631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2020.1824631</ArticleId>
            <ArticleId IdType="pmc">PMC7781712</ArticleId>
            <ArticleId IdType="pubmed">33457101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai L, Qin X, Xu Z, Song Y, Jiang H, Wu Y, Ruan H, Chen J. 2019. Comparison of Cytotoxicity Evaluation of Anticancer Drugs between Real-Time Cell Analysis and CCK-8 Method. ACS Omega. 4(7):12036–12042. 10.1021/acsomega.9b01142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsomega.9b01142</ArticleId>
            <ArticleId IdType="pmc">PMC6682106</ArticleId>
            <ArticleId IdType="pubmed">31460316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannelli G, Villa E, Lahn M. 2014. Transforming growth factor-beta as a therapeutic target in hepatocellular carcinoma. Cancer Res. 74(7):1890–1894. 10.1158/0008-5472.CAN-14-0243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-0243</ArticleId>
            <ArticleId IdType="pubmed">24638984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses, HL, Arteaga, CL., 2003. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol. 23(23):8691–8703. DOI:10.1128/mcb.23.23.8691-8703.2003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mcb.23.23.8691-8703.2003</ArticleId>
            <ArticleId IdType="pmc">PMC262670</ArticleId>
            <ArticleId IdType="pubmed">14612410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma TT, Meng XM. 2019. TGF-beta/Smad and Renal Fibrosis. Adv Exp Med Biol. 1165:347–364. 10.1007/978-981-13-8871-2_16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-981-13-8871-2_16</ArticleId>
            <ArticleId IdType="pubmed">31399973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, Zhang Z, Song C, Deng H, Yang R, Zhou L, Sun Y, Zhang Q. 2019. Glaucocalyxin A reverses EMT and TGF-beta1-induced EMT by inhibiting TGF-beta1/Smad2/3 signaling pathway in osteosarcoma. Chem Biol Interact. 307:158–166. 10.1016/j.cbi.2019.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cbi.2019.05.005</ArticleId>
            <ArticleId IdType="pubmed">31059706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al. 2015. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 527(7579):472–476. DOI:10.1038/nature15748</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15748</ArticleId>
            <ArticleId IdType="pmc">PMC4662610</ArticleId>
            <ArticleId IdType="pubmed">26560033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fei F, Zhang D, Yang Z, Wang S, Wang X, Wu Z, Wu Q, Zhang S. 2015. The number of polyploid giant cancer cells and epithelial-mesenchymal transition-related proteins are associated with invasion and metastasis in human breast cancer. J Exp Clin Cancer Res. 34(1):158. 10.1186/s13046-015-0277-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-015-0277-8</ArticleId>
            <ArticleId IdType="pmc">PMC4690326</ArticleId>
            <ArticleId IdType="pubmed">26702618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J. 2012. IL-1beta promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol Cancer. 11(1):87. 10.1186/1476-4598-11-87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-11-87</ArticleId>
            <ArticleId IdType="pmc">PMC3532073</ArticleId>
            <ArticleId IdType="pubmed">23174018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suarez-Causado A, Caballero-Diaz D, Bertran E, Roncero C, Addante A, Garcia-Alvaro M, Fernández M, Herrera B, Porras A, Fabregat I, et al. 2015. HGF/c-Met signaling promotes liver progenitor cell migration and invasion by an epithelial-mesenchymal transition-independent, phosphatidyl inositol-3 kinase-dependent pathway in an in vitro model. Biochim Biophys Acta. 1853(10 Pt A):2453–2463. DOI:10.1016/j.bbamcr.2015.05.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2015.05.017</ArticleId>
            <ArticleId IdType="pubmed">26001768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colmenares C, Stavnezer E. 1989. The ski oncogene induces muscle differentiation in quail embryo cells. Cell. 59(2):293–303. 10.1016/0092-8674(89)90291-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(89)90291-2</ArticleId>
            <ArticleId IdType="pubmed">2553267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buess M, Terracciano L, Reuter J, Ballabeni P, Boulay JL, Laffer U, Metzger U, Herrmann R, Rochlitz CF. 2004. Amplification of SKI is a prognostic marker in early colorectal cancer. Neoplasia. 6(3):207–212. 10.1593/neo.03442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/neo.03442</ArticleId>
            <ArticleId IdType="pmc">PMC1502098</ArticleId>
            <ArticleId IdType="pubmed">15153332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuchi M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Sohda M, Manda R, Tsukada K, Kato H, Kuwano H, et al. 2004. Increased expression of c-Ski as a co-repressor in transforming growth factor-beta signaling correlates with progression of esophageal squamous cell carcinoma. Int J Cancer. 108(6):818–824. DOI:10.1002/ijc.11651</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.11651</ArticleId>
            <ArticleId IdType="pubmed">14712482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heider TR, Lyman S, Schoonhoven R, Behrns KE. 2007. Ski promotes tumor growth through abrogation of transforming growth factor-beta signaling in pancreatic cancer. Ann Surg. 246(1):61–68. 10.1097/SLA.0b013e318070cafa.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/SLA.0b013e318070cafa</ArticleId>
            <ArticleId IdType="pmc">PMC1899223</ArticleId>
            <ArticleId IdType="pubmed">17592292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reed JA, Bales E, Xu W, Okan NA, Bandyopadhyay D, Medrano EE. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res. 2001;61(22):8074–8078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11719430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritter M, Kattmann D, Teichler S, Hartmann O, Samuelsson MK, Burchert A, Bach J-P, Kim TD, Berwanger B, Thiede C, et al. 2006. Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. Leukemia. 20(3):437–443. DOI:10.1038/sj.leu.2404093</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.leu.2404093</ArticleId>
            <ArticleId IdType="pubmed">16424870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinagawa T, Nomura T, Colmenares C, Ohira M, Nakagawara A, Ishii S. 2001. Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice. Oncogene. 20(56):8100–8108. 10.1038/sj.onc.1204987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1204987</ArticleId>
            <ArticleId IdType="pubmed">11781823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colmenares C, Heilstedt HA, Shaffer LG, Schwartz S, Berk M, Murray JC, Stavnezer E. 2002. Loss of the SKI proto-oncogene in individuals affected with 1p36 deletion syndrome is predicted by strain-dependent defects in Ski-/- mice. Nat Genet. 30(1):106–109. 10.1038/ng770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng770</ArticleId>
            <ArticleId IdType="pubmed">11731796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie M, Wu X, Zhang J, Zhang J, Li X. 2017. Ski regulates Smads and TAZ signaling to suppress lung cancer progression. Mol Carcinog. 56(10):2178–2189. 10.1002/mc.22661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.22661</ArticleId>
            <ArticleId IdType="pubmed">28398634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Liu X, Eaton EN, Lane WS, Lodish HF, Weinberg RA. 1999. Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling. Mol Cell. 4(4):499–509. 10.1016/s1097-2765(00)80201-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1097-2765(00)80201-4</ArticleId>
            <ArticleId IdType="pubmed">10549282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tecalco-Cruz AC, Rios-Lopez DG, Vazquez-Victorio G, Rosales-Alvarez RE, Macias-Silva M. 2018. Transcriptional cofactors Ski and SnoN are major regulators of the TGF-beta/Smad signaling pathway in health and disease. Signal Transduct Target Ther. 3:15. 10.1038/s41392-018-0015-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-018-0015-8</ArticleId>
            <ArticleId IdType="pmc">PMC5992185</ArticleId>
            <ArticleId IdType="pubmed">29892481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Scolan E, Zhu Q, Wang L, Bandyopadhyay A, Javelaud D, Mauviel A, Sun L, Luo K. 2008. Transforming growth factor-beta suppresses the ability of Ski to inhibit tumor metastasis by inducing its degradation. Cancer Res. 68(9):3277–3285. 10.1158/0008-5472.CAN-07-6793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-6793</ArticleId>
            <ArticleId IdType="pubmed">18451154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Takaku M, Zou LY, Gu AD, Chou WC, Zhang G, Wu B, Kong Q, Thomas SY, Serody JS, et al. 2017. Reversing SKI–SMAD4-mediated suppression is essential for TH17 cell differentiation. Nature. 551(7678):105–109. 10.1038/nature24283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature24283</ArticleId>
            <ArticleId IdType="pmc">PMC5743442</ArticleId>
            <ArticleId IdType="pubmed">29072299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling J, Cai Z, Jin W, Zhuang X, Kan L, Wang F, Ye, X. 
2019. Silencing of c-Ski augments TGF-b1-induced epithelial-mesenchymal transition in cardiomyocyte H9C2 cells. Cardiol J. 26(1):66–76. DOI:10.5603/CJ.a2018.0009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/CJ.a2018.0009</ArticleId>
            <ArticleId IdType="pmc">PMC8086681</ArticleId>
            <ArticleId IdType="pubmed">29570207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji X, Naito Y, Weng H, Ma X, Endo K, Kito N, Yanagawa N, YU Y, LI J, Iwai N, et al. 2013. Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways. Biomed Res. 34(6):309–319. DOI:10.2220/biomedres.34.309</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2220/biomedres.34.309</ArticleId>
            <ArticleId IdType="pubmed">24389407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King
TE
Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina, E, Hopkins, PM, Kardatzke, D, Lancaster, L.. 
2014. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 370(22):2083–2092. DOI:10.1056/NEJMoa1402582</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1402582</ArticleId>
            <ArticleId IdType="pubmed">24836312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon HY, Kim DS, Song JW. 2019. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis. Respiration. 97(3):242–251. 10.1159/000492937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000492937</ArticleId>
            <ArticleId IdType="pubmed">30332670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lima-Posada I, Fontana F, Perez-Villalva R, Berman-Parks N, Bobadilla NA. 2019. Pirfenidone prevents acute kidney injury in the rat. BMC Nephrol. 20(1):158. 10.1186/s12882-019-1364-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12882-019-1364-4</ArticleId>
            <ArticleId IdType="pmc">PMC6505112</ArticleId>
            <ArticleId IdType="pubmed">31068174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>RamachandraRao SP, Zhu Y, Ravasi T, McGowan TA, Toh I, Dunn SR, Okada S, Shaw MA, Sharma K. 2009. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol. 20(8):1765–1775. 10.1681/ASN.2008090931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2008090931</ArticleId>
            <ArticleId IdType="pmc">PMC2723978</ArticleId>
            <ArticleId IdType="pubmed">19578007</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
